2021
Miglustat Therapy for SCARB2-Associated Action Myoclonus–Renal Failure Syndrome
Quraishi IH, Szekely AM, Shirali AC, Mistry PK, Hirsch LJ. Miglustat Therapy for SCARB2-Associated Action Myoclonus–Renal Failure Syndrome. Neurology Genetics 2021, 7: e614. PMID: 34337151, PMCID: PMC8320328, DOI: 10.1212/nxg.0000000000000614.Peer-Reviewed Original ResearchAction myoclonus-renal failure syndromeNeurologic symptomsAction myoclonusFailure syndromeProgressive myoclonic epilepsySubstrate reduction therapyWhole-exome sequencingMiglustat therapyAvailable medicationsEarly mortalityReduction therapyMyoclonic epilepsySteady worseningGaucher diseaseMyoclonusGlycosphingolipid metabolismExome sequencingGene mutationsGlucosylceramide accumulationPatientsSeizuresMiglustatSyndromeTherapySymptoms
2000
The clinical expression of Gaucher disease correlates with genotype: Data from 570 patients
Scott C, Pastores G, Andersson H, Charrow J, Kaplan P, Kolodny E, Mistry P, Rosenbloom B, Wappner R, Weinreb N. The clinical expression of Gaucher disease correlates with genotype: Data from 570 patients. Genetics In Medicine 2000, 2: 65-65. DOI: 10.1097/00125817-200001000-00059.Peer-Reviewed Original ResearchN370S/N370SN370S/L444PNeurologic symptomsL444P/L444PL444P/L444P genotypeCommon genotypeLarger spleen volumeSevere neurologic symptomsAortic valve calcificationCommon lysosomal storage diseaseDeficiency of glucocerebrosidaseRadiologic evidenceClinical symptomsValve calcificationHematologic changesSpleen volumeClinical signatureClinical expressionBone diseaseLysosomal storage diseaseN370S allelePatientsAdult disordersBone fracturesGaucher disease